arrow
S

Steven C. Wallis

the frazer institute
H指数:44
被引数:7,383

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters

超滤法测定危重患者中头孢吡肟、氯唑西林、美罗培南、哌拉西林和他唑巴坦的蛋白结合率:设备选择至关重要

2026-08-290
OAAI
Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy

万古霉素优化给药方案用于接受肾脏替代治疗的危重患者

2026-08-040
OA
Plasma and subcutaneous interstitial fluid vancomycin and gentamicin concentrations in three patients undergoing open abdominal aortic aneurysm repair

血浆和皮下间质液中万古霉素和庆大霉素浓度在3例接受开放性腹主动脉瘤修复术患者中的比较

2026-05-230
PRE
Population pharmacokinetics of polymyxin B in critically ill patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa infections

多药耐药鲍曼不动杆菌和铜绿假单胞菌感染危重患者中多黏菌素B的群体药代动力学

2026-04-210
OAAI
Population pharmacokinetics of total and free ceftriaxone in critically ill and non-critically ill hospitalised adult patients

曲松钠总浓度和游离浓度在危重和非危重住院成年患者中的群体药代动力学

2026-04-210
OAAI
Meropenem dosing optimization on day 1 and steady state in critically ill patients without significant renal impairment

美罗培南在第一天给药剂量优化及在无显著肾功能损害的重症患者的稳态给药

2025-10-290
OA
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy

美罗培南和哌拉西林/他唑巴坦针对接受肾脏替代治疗的危重患者的优化给药方案

2025-08-130
OA
Tranexamic acid did not attenuate the acute rise in plasma syndecan-1 in a severely injured cohort: a laboratory analysis of the PATCH clinical trial

氨甲环酸并未减轻严重受伤队列中血浆 Syndecan-1 的急性升高:PATCH 临床试验的实验室分析

2025-07-110
OA
Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19

瑞德西韦及其代谢物GS-441524在住院COVID-19患者中的群体药代动力学模型构建

2025-04-220
OA